Skip to content
CancerIndex

Publication

Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia With NCOR1-LYN Fusion.

Authors not recorded

Front Oncol2020PMID 32266142PMC7098965stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (3)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 3

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
32266142
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
LYN Fusion1
(diagnostic)B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-LikeDiagnosticCSupports Positive3accepted
EID12809

In this 2020 case report, the authors present a pediatric patient with relapsed B-lymphoblastic leukemia (B-ALL), providing critical evidence for the diagnostic and therapeutic role of LYN fusions. Th… (full text at CIViC)

PMID 32266142 · Dai et al., 2020 · Open in CIViC

civic